Novo Nordisk beats on Wegovy sales, expects slower 2025 growth
Novo's earnings results Wednesday differ from Eli Lilly's, whose stock slid on slower-than-expected sales of weight loss drugs towards the end of the year. Novo saw But Novo said Wednesday it expects slower growth in 2025 compared to the prior year.
Ozempic and Wegovy maker Novo Nordisk quieted Wall Street's concerns with its fourth-quarter results and 2025 outlook.
Weight loss drug users are spending up to $690 less per year on groceries. Find out which foods they’re ditching the most.
Drug industry calls out telehealth company Hims & Hers' Super Bowl ad touting its knock-off weight loss medications.
MarketWatch on MSN12d
This Wegovy user spent $5,000 on a new wardrobe after losing 80 pounds — and she’s not aloneTori Allen says she’s thrilled to have lost 80 pounds since she went on Wegovy, one of the GLP-1 drugs that more and more ...
New GLP-1RA weight loss drugs like Like Ozempic and Wegovy have become extremely popular in recent months but researchers ...
Donald Trump's renewed push to take control of Greenland is setting off a high-stakes showdown with Denmark, a small country ...
While it may seem strange that politics could impact the price of popular weight loss drugs, it is a definite possibility.
While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback